NCT01892930

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery

Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Roswell Park Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot clinical trial studies stereotactic body radiation therapy in treating patients with metastatic kidney cancer undergoing surgery. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Detailed description

PRIMARY OBJECTIVES: I. Assess the impact of stereotactic body radiation therapy (SBRT) on the immune system in patients with metastatic renal cell carcinoma (RCC). SECONDARY OBJECTIVES: I. Assess changes in immune parameters prior to radiation, post radiation and post nephrectomy. TERTIARY OBJECTIVES: I. Assess surgical parameters for partial or radical nephrectomy post SBRT. OUTLINE: Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29. After completion of study treatment, patients are followed up at 30 days.

Conditions

• Recurrent Renal Cell Cancer
• Stage IV Renal Cell Cancer

Interventions

Type	Name	Description
RADIATION	stereotactic body radiation therapy	Undergo SBRT
PROCEDURE	therapeutic conventional surgery	Undergo partial or radical nephrectomy
OTHER	laboratory biomarker analysis	Correlative studies

Timeline

• Start date: 2013-07-11
• Primary completion: 2015-12-30
• Completion: 2016-12-30
• First posted: 2013-07-08
• Last updated: 2022-07-22

Locations

1 site across 1 country: United States